NASDAQ:APRE Aprea Therapeutics Q2 2025 Earnings Results & Report $0.45 +0.05 (+11.52%) Closing price 04:00 PM EasternExtended Trading$0.45 0.00 (-0.46%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aprea Therapeutics beat analyst earnings expectations in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$0.53 versus the -$0.77 consensus estimate, while revenue was $118 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 12, 2025TimeBefore Market OpensConference Call8:00 AM ET Aprea Therapeutics EPS ResultsActual EPS-$0.53Consensus EPS -$0.77Beat/MissBeat by +$0.24One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersAprea Therapeutics Revenue ResultsActual Revenue$118 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aprea Therapeutics Q2 2025 Earnings FAQ Did Aprea Therapeutics beat earnings estimates for Q2 2025? Aprea Therapeutics (NASDAQ:APRE) reported earnings of -$0.53 per share for Q2 2025, beating the consensus estimate of -$0.77. The report was announced on Tuesday, August 12, 2025. What was Aprea Therapeutics' revenue for Q2 2025? Aprea Therapeutics reported revenue of $118 thousand for Q2 2025. Aprea Therapeutics Earnings HeadlinesAprea Therapeutics, Inc. (NASDAQ:APRE) Stock Has Average Price Target of $2.80November 13, 2026 | americanbankingnews.comAprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceNovember 5, 2026 | globenewswire.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 17 at 1:00 AM | Behind the Markets (Ad)Aprea Q3 Loss Widens On R&D Costs; Updated APR-1051 Phase 1 Data Due November 20November 5, 2026 | rttnews.comAprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 4, 2026 | marketscreener.comMAprea Therapeutics Announces Third Quarter 2026 Financial ResultsNovember 4, 2026 | globenewswire.comSee More Aprea Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email. Email Address About Aprea TherapeuticsAprea Therapeutics (NASDAQ:APRE) is a clinical-stage biotechnology company focused on developing investigational cancer treatments. Its research centers on the DNA damage response, a network of cellular processes that helps repair damaged DNA and that can be targeted in some cancers. The company’s pipeline has included ATR inhibitors, a class of experimental medicines intended to disrupt cancer cells’ ability to respond to DNA damage. Aprea has evaluated these candidates in early-stage clinical research; they are investigational and have not been established as approved treatments.View Aprea Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.